Svetlana Cherlin
Overview
Explore the profile of Svetlana Cherlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cherlin S, Wason J
Contemp Clin Trials
. 2024 Jul;
144:107620.
PMID: 38977178
We propose a Cross-validated ADaptive ENrichment design (CADEN) in which a trial population is enriched with a subpopulation of patients who are predicted to benefit from the treatment more than...
2.
Morton M, Wilson N, Homer T, Simms L, Steel A, Maier R, et al.
BMJ Open
. 2023 Aug;
13(8):e071906.
PMID: 37562935
Introduction: Bronchiectasis is a long-term lung condition, with dilated bronchi, chronic inflammation, chronic infection and acute exacerbations. Recurrent exacerbations are associated with poorer clinical outcomes such as increased severity of...
3.
Grayling M, Bigirumurame T, Cherlin S, Ouma L, Zheng H, Wason J
BMC Rheumatol
. 2021 Jul;
5(1):21.
PMID: 34210348
Background: Despite progress that has been made in the treatment of many immune-mediated inflammatory diseases (IMIDs), there remains a need for improved treatments. Randomised controlled trials (RCTs) provide the highest...
4.
Cherlin S, Wason J
Biostatistics
. 2021 Jun;
24(2):327-344.
PMID: 34165151
The existing cross-validated risk scores (CVRS) design has been proposed for developing and testing the efficacy of a treatment in a high-efficacy patient group (the sensitive group) using high-dimensional data...
5.
Vergis N, Phillips R, Cornelius V, Katsarou A, Youngstein T, Cook L, et al.
Trials
. 2021 Apr;
22(1):270.
PMID: 33845867
Objectives: The primary objective of MATIS is to determine the efficacy of ruxolitinib (RUX) or fostamatinib (FOS) compared to standard of care (SOC) with respect to reducing the proportion of...
6.
Castellucci L, Almeida L, Cherlin S, Fakiola M, Francis R, Carvalho E, et al.
Clin Infect Dis
. 2020 Aug;
72(10):e515-e525.
PMID: 32830257
Background: Our goal was to identify genetic risk factors for cutaneous leishmaniasis (CL) caused by Leishmania braziliensis. Methods: Genotyping 2066 CL cases and 2046 controls using Illumina HumanCoreExomeBeadChips provided data...
7.
Cherlin S, Lewis M, Plant D, Nair N, Goldmann K, Tzanis E, et al.
Ann Rheum Dis
. 2020 Aug;
79(11):1446-1452.
PMID: 32732242
Objectives: In this study, we sought to investigate whether there was any association between genetically regulated gene expression (as predicted using various reference panels) and anti-tumour necrosis factor (anti-TNF) treatment...
8.
Cherlin S, Wason J
Stat Med
. 2020 Jul;
39(24):3285-3298.
PMID: 32662542
There is the potential for high-dimensional information about patients collected in clinical trials (such as genomic, imaging, and data from wearable technologies) to be informative for the efficacy of a...
9.
Cherlin S, Plant D, Taylor J, Colombo M, Spiliopoulou A, Tzanis E, et al.
Genet Epidemiol
. 2018 Oct;
42(8):754-771.
PMID: 30311271
Although a number of treatments are available for rheumatoid arthritis (RA), each of them shows a significant nonresponse rate in patients. Therefore, predicting a priori the likelihood of treatment response...
10.
Cherlin S, Howey R, Cordell H
BMC Proc
. 2018 Oct;
12(Suppl 9):38.
PMID: 30275888
Background: In a typical genome-enabled prediction problem there are many more predictor variables than response variables. This prohibits the application of multiple linear regression, because the unique ordinary least squares...